Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations
- 14 March 2022
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , 594-599
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation (WEST15A0)
- Cystic Fibrosis Foundation (KESSLE17AB0)
- Cystic Fibrosis Foundation (FLUME15A0)
- Cystic Fibrosis Foundation (SANDER17AB0)
- Cystic Fibrosis Foundation (WEST175Y)
- Cystic Fibrosis Foundation (HELTSH15A0)
- Cystic Fibrosis Foundation (FLUME17AB0)
- Cystic Fibrosis Foundation (SANDER14A0)
- Cystic Fibrosis Foundation (WEST17AB0)
- Cystic Fibrosis Foundation (GOSS15A0)
- National Institutes of Health (UL1 TR001450)
- National Institutes of Health (P30 DK089507)
- National Institutes of Health (02781610)
- CHEST Foundation
- Gilead Sciences
- National Center for Advancing Translational Sciences
This publication has 22 references indexed in Scilit:
- Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosisJournal of Cystic Fibrosis, 2017
- Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United StatesCurrent Medical Research and Opinion, 2017
- Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosisJournal of Cystic Fibrosis, 2016
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRNew England Journal of Medicine, 2015
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Cost of Illness of Cystic Fibrosis in GermanyPharmacoEconomics, 2012
- Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical TrialValue in Health, 2012
- Regression analysis of incomplete medical cost dataStatistics in Medicine, 2003
- On the use of survival analysis techniques to estimate medical care costsJournal of Health Economics, 1999
- Estimating the costs attributable to a disease with application to ovarian cancerJournal of Clinical Epidemiology, 1996